Scopus BioPharma (NASDAQ:SCPS) Shares Down 8.3%
Scopus BioPharma (NASDAQ:SCPS) Shares Down 8.3%
Shares of Scopus BioPharma Inc. (NASDAQ:SCPS – Get Rating) dropped 8.3% on Wednesday . The company traded as low as $0.10 and last traded at $0.11. Approximately 21,957 shares traded hands during mid-day trading, a decline of 60% from the average daily volume of 55,127 shares. The stock had previously closed at $0.12.
周三，Scopus BioPharma Inc.（纳斯达克股票代码：SCPS — 获取评级）的股价下跌了8.3％。该公司的交易价格低至0.10美元，最后一次交易价格为0.11美元。午盘交易中约有21,957股股票交易，较平均每日交易量55,127股下降了60％。该股此前收于0.12美元。
Scopus BioPharma Stock Down 8.3 %
Scopus BioPharma 股票下跌 8.3%
The business's fifty day moving average price is $0.17 and its two-hundred day moving average price is $0.28.
该公司的五十天移动平均线价格为0.17美元，其两百天移动平均线价格为0.28美元。
Institutional Investors Weigh In On Scopus BioPharma
机构投资者对 Scopus BioPharma 表示关注
An institutional investor recently raised its position in Scopus BioPharma stock. Renaissance Technologies LLC grew its stake in shares of Scopus BioPharma Inc. (NASDAQ:SCPS – Get Rating) by 438.4% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 112,523 shares of the company's stock after acquiring an additional 91,623 shares during the period. Renaissance Technologies LLC owned about 0.53% of Scopus BioPharma worth $78,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 2.16% of the company's stock.
一位机构投资者最近提高了其在Scopus BioPharma股票中的头寸。根据Renaissance Technologies LLC向美国证券交易委员会发布的最新披露，该公司在第一季度将其在Scopus BioPharma Inc.（纳斯达克股票代码：SCPS — 获取评级）的股份增加了438.4％。该机构投资者在此期间又收购了91,623股股票后，拥有该公司的112,523股股票。截至最近一个季度末，Renaissance Technologies LLC拥有Scopus BioPharma约0.53％的股份，价值7.8万美元。对冲基金和其他机构投资者拥有该公司2.16％的股票。
Scopus BioPharma Company Profile
Scopus BioPharma 公司简介
Scopus BioPharma Inc, a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase.
Scopus BioPharma Inc是一家临床阶段的生物制药公司，专注于开发针对严重疾病的变革性疗法。该公司主导的开发项目是用于治疗各种癌症的免疫肿瘤学基因疗法。它提供Duet Platform，一种cpG信号传导器和转录3（STAT3）抑制剂的激活剂；以及合理设计的、口服的、双作用、混合和小分子的 MRI-1867，是内源性大麻素系统/大麻素受体1的反向激动剂，也是诱导性一氧化氮合酶的抑制剂。
See Also
另见
- Get a free copy of the StockNews.com research report on Scopus BioPharma (SCPS)
- Procter & Gamble Earnings: A Gamble Worth Taking
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
- 免费获取 StockNews.com 关于 Scopus BioPharma（SCPS）的研究报告的副本
- 宝洁公司收益：一场值得一试的赌博
- 股市下滑，经济报告描绘了经济的阴暗前景
- Nu Holdings 的股票与沃伦·巴菲特有什么关系？
- J.B. Hunt 持平，物流公司成为人们关注的焦点
- 英特尔股票即将爆发吗？
Receive News & Ratings for Scopus BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scopus BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
接收Scopus BioPharma Daily的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Scopus BioPharma及相关公司的最新新闻和分析师评级的简明每日摘要。